Update shared on 10 Dec 2025
Analysts have modestly raised their price target on hVIVO, citing a slightly higher assumed discount rate and marginally improved long term growth and valuation assumptions. Together, these factors support an updated fair value of approximately £0.17 per share.
What's in the News
- hVIVO congratulated client Cidara Therapeutics on a definitive agreement to be acquired by Merck Sharp and Dohme for approximately 9.2 billion dollars, highlighting hVIVO's role in accelerating development of Cidara's lead influenza candidate CD388 through early human challenge data and ongoing Phase III support (Key Developments).
- CD388, a long acting, strain agnostic antiviral designed to prevent influenza A and B in high risk individuals, met all primary and secondary endpoints in Phase IIb, supported by data from an hVIVO conducted randomized, double blind influenza human challenge study in 59 volunteers (Key Developments).
- hVIVO presented positive data on its new contemporary strain human metapneumovirus challenge model at ESWI, showing high infection and symptomatic attack rates and strong virology profiles, and confirming readiness for vaccine and antiviral trials (Key Developments).
- The company unveiled the first commercially available SARS CoV 2 Omicron BA5 human challenge model and a robust RSV B model, expanding its respiratory challenge portfolio and supporting next generation vaccine and antiviral efficacy testing (Key Developments).
- hVIVO issued 2026 guidance for high single digit revenue growth, driven by expansion of diversified services and a move toward more normal human challenge trial activity levels (Key Developments).
Valuation Changes
- Fair Value per Share, unchanged at approximately £0.17, with the updated model maintaining the same implied equity valuation.
- Discount Rate, risen slightly from about 8.9 percent to just over 9.1 percent, reflecting a modest increase in the assumed cost of capital.
- Revenue Growth, effectively unchanged at around 2.2 percent, indicating no material shift in top line growth expectations.
- Net Profit Margin, essentially flat at roughly 4.5 percent, suggesting stable long term profitability assumptions.
- Future P/E, risen slightly from about 60.4x to 60.7x, implying a marginal increase in the valuation multiple applied to forward earnings.
Have other thoughts on hVIVO?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.